TY - JOUR
T1 - Systemically circulating colitogenic memory CD4+ T cells may be an ideal target for the treatment of inflammatory bowel diseases
AU - Kanai, Takanori
AU - Watanabe, Mamoru
AU - Hibi, Toshifumi
N1 - Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2009/12
Y1 - 2009/12
N2 - Inflammatory bowel diseases (IBD) are thought to be caused by a complex interaction of genetic, immunological, and environmental factors. Why is it that once an IBD develops it lasts a long time? Considering this simple question, we propose that coliotogenic memory CD4+T cells that remember the prototype of the disease in each patient are formed in IBD at the onset, and, perceiving them as "benign T-cell leukemia"-like lifelong memory CD4+T cells that hematogenously spread throughout the body, we thus propose that systemic circulating colitogenic memory CD4+T cells would be an ideal target for the treatment of IBD. Accordingly, selective depletion of colitogenic memory CD4+T cells by leukocytapheresis and blockade of circulation of colitogenic memory CD4+T cells by a newly developed immunosuppressant, FTY720, may be associated with dramatic efficacy and a marked reduction of inflammatory cytokines produced by activated leucocytes. We here describe the immunological pathogenesis focusing on the generation of circulating colitogenic memory CD4+T cells and the possible logics of leukocytapheresis and FTY720 for the treatment of IBD.
AB - Inflammatory bowel diseases (IBD) are thought to be caused by a complex interaction of genetic, immunological, and environmental factors. Why is it that once an IBD develops it lasts a long time? Considering this simple question, we propose that coliotogenic memory CD4+T cells that remember the prototype of the disease in each patient are formed in IBD at the onset, and, perceiving them as "benign T-cell leukemia"-like lifelong memory CD4+T cells that hematogenously spread throughout the body, we thus propose that systemic circulating colitogenic memory CD4+T cells would be an ideal target for the treatment of IBD. Accordingly, selective depletion of colitogenic memory CD4+T cells by leukocytapheresis and blockade of circulation of colitogenic memory CD4+T cells by a newly developed immunosuppressant, FTY720, may be associated with dramatic efficacy and a marked reduction of inflammatory cytokines produced by activated leucocytes. We here describe the immunological pathogenesis focusing on the generation of circulating colitogenic memory CD4+T cells and the possible logics of leukocytapheresis and FTY720 for the treatment of IBD.
KW - Colitogenic memory CD4 T cells
KW - FTY720
KW - Inflammatory bowel disease
KW - Leukocytapheresis
UR - http://www.scopus.com/inward/record.url?scp=75149184215&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=75149184215&partnerID=8YFLogxK
U2 - 10.2302/kjm.58.203
DO - 10.2302/kjm.58.203
M3 - Review article
C2 - 20037283
AN - SCOPUS:75149184215
VL - 58
SP - 203
EP - 209
JO - Keio Journal of Medicine
JF - Keio Journal of Medicine
SN - 0022-9717
IS - 4
ER -